Mirum Pharmaceuticals, Inc. (MIRM) is a Biotechnology company in the Healthcare sector, currently trading at $96.90. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of MIRM = $1,392.61 (+1337.2% from the current price, the stock appears undervalued). Analyst consensus target is MIRM = $117 (+20.4% upside).
Valuation: MIRM trades at a trailing Price-to-Earnings (P/E) of -208 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.16.
Financials: revenue is $521M, +92.5%/yr average growth. Net income is $23M (loss), growing at +33.1%/yr. Net profit margin is -4.5% (negative). Gross margin is 80.7% (-3.2 pp trend).
Balance sheet: total debt is $319M against $315M equity (Debt-to-Equity (D/E) ratio 1.02, moderate). Current ratio is 2.67 (strong liquidity). Debt-to-assets is 37.9%. Total assets: $843M.
Analyst outlook: 18 / 18 analysts rate MIRM as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 52/100 (Partial), Growth 100/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 61/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
